UK Markets closed

Sanofi (SNYNF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
96.600.00 (0.00%)
At close: 3:25PM EDT
Sign in to post a message.
  • M
    Metal Ox
    $TBIO shares cashed this week by Sanofi. With mrna now in its portfolio, is $SNY worth considering, or dead money Investment? What’s the case for buying Sanofi, or is there a case?
  • I
    Imelda
    It will be very hard for me to buy this stock.I will always remember the dead children in the Philippines who was given the Sanofi Dengue vaccine.More than a dozen,No money could ever buy those lives back.
  • P
    Phil
    Sanofi’s Covid vaccine is now in its Phase 3 trial, yawn........
  • A
    A
    a competing offer would seem appropiate: market values of BNTX, MRNA, CVAC do not appear to have been a consideration in the pricing of the Sanofi offer. TBIO near the readout of their phase 2/3 covid19 vaccine trial. The current partnership agreement appears to be a better value for a long term TBIO stockholder. There are many big pharma and biotech companies who are in a position to make a better offer.
  • P
    PIN
    As long as you have snakes as governors - like in Florida or Texas, which by the way account for over 33% of all new Covid cases - we need more vaccines and we can make money by buying stocks in vaccine making cos. Sanofi is therefore a buy after trying to acquire this new Bio co.
  • S
    Saint Preferred
    "If you don’t get vaccinated, you will get Covid at this point’: Doctor"

    More fear mongering DEMO-NONSENSE.
  • A
    A
    a successful mRNA vaccine in covid19 or influenza would be a tremendous value to current shareholders. A discounted cash flow of that success would value the company closer to other mRNA companies with successful a drug. I took that gamble
  • E
    Esther
    Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development
  • P
    Phil
    French drug maker Sanofi says it will help manufacture 125 million doses of the coronavirus vaccine developed by rivals Pfizer and BioNTech, while its own vaccine candidate faces delays.
  • M
    Madeleine
    Watch for this to pop in the EU, as MRNA being looked at more carefully for adverse reaction
  • E
    Esther
    French-made Sanofi Covid vaccine moves a step closer to use in EU
  • J
    Jim
    Per Market Beat; SNY had its price target raised by analysts at HC Wainwright from $703.00 to $729.00. They now have a "buy" rating on the stock. This represents a 1316.4% upside from the current price of $51.47.
  • G
    Garza 759ify
    SNY market cap 129 billion shares outstanding 2.50 billion employees 99412 share price 51,76$
  • b
    b
    Goldman Sachs Group Inc. increased its stake in shares of Translate Bio, Inc. (NASDAQ:TBIO) by 62.2% in the 1st qtr. The firm owned 1,592,511 shares of the company’s stock after buying an additional 610,590 shares during the quarter. Goldman Sachs Group Inc.’s holdings in Translate Bio were worth $26,261,000 at the end of the most recent reporting period.
  • P
    Phil
    Sanofi still doesn't have a COVID-19 vaccine on the horizon, the analyst ratings on this stock are......drum roll please......
  • B
    Big Toe
    Thank you ladies and gentlemen for buying KDMN have a nice day
  • J
    Jasper
    Compared to Pfizer, Moderna and AZ this stock is worth about 75#$%$
  • L
    Lester
    Regret buying this stock...
  • s
    steve
    U.S. to pay $2.1 billion to Sanofi, GSK, in COVID-19 vaccine deal